SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"SARS‐CoV‐2‐neutralising Monoclonal Antibodies for Treatment of COVID‐19." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/433921/all/SARS‐CoV‐2‐neutralising_monoclonal_antibodies_for_treatment_of_COVID‐19.
SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433921/all/SARS‐CoV‐2‐neutralising_monoclonal_antibodies_for_treatment_of_COVID‐19. Accessed December 12, 2024.
SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433921/all/SARS‐CoV‐2‐neutralising_monoclonal_antibodies_for_treatment_of_COVID‐19
SARS‐CoV‐2‐neutralising Monoclonal Antibodies for Treatment of COVID‐19 [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 December 12]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/433921/all/SARS‐CoV‐2‐neutralising_monoclonal_antibodies_for_treatment_of_COVID‐19.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19
ID - 433921
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/433921/all/SARS‐CoV‐2‐neutralising_monoclonal_antibodies_for_treatment_of_COVID‐19
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -